Processa Pharmaceuticals (PCSA) Net Cash Flow (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Net Cash Flow came in at -$3.8 million in Q1 2026, down 325.47% YoY from $1.7 million in Q1 2025, and down 4961.29% on a QoQ basis from $79113.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Net Cash Flow (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Net Cash Flow data on file, last reported at -$3.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 325.47% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$370834.0 (up 93.84% YoY) and the FY2025 annual result came in at $4.3 million, up 223.21% from the prior year.
- Net Cash Flow slipped to -$3.8 million in Q1 2026, from $79113.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $4.2 million in Q1 2023 to a low of -$3.8 million in Q1 2026.
- A 5-year average of -$821489.6 and a median of -$2.1 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 301.53% — and 2026, when it sank 325.47%.
- Tracing PCSA's Net Cash Flow over 5 years: stood at -$2.6 million in 2022, then rose by 15.54% to -$2.2 million in 2023, then gained by 21.09% to -$1.7 million in 2024, then jumped by 104.65% to $79113.0 in 2025, then sank by 4961.29% to -$3.8 million in 2026.
- The last three Net Cash Flow figures came in at -$3.8 million (Q1 2026), $79113.0 (Q4 2025), and -$643836.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | -1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.85 Mn |
| Mar 31, 2026 | -3.85 Mn |
| Dec 31, 2025 | 79,113.00 |
| Dec 31, 2025 | 79,113.00 |
| Sep 30, 2025 | -643,836.00 |
| Sep 30, 2025 | -643,836.00 |
| Jun 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Sep 30, 2024 | -2.68 Mn |
| Sep 30, 2024 | -2.68 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | 4.21 Mn |
| Mar 31, 2024 | 4.21 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |